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Recombinant bovine adenovirus is being developed as a live vector for animal vaccination and for human gene therapy. In
this study, two replication-competent bovine adenovirus 3 (BAV-3) recombinants (BAV331 and BAV338) expressing bovine
viral diarrhea virus (BVDV) glycoprotein E2 in the early region 3 (E3) of BAV-3 were constructed. Recombinant BAV331
contains chemically synthesized E2 gene (nucleotides modified to remove internal cryptic splice sites) under the control of
BAV-3 E3/major late promoter (MLP), while recombinant BAV338 contains original E2 gene under the control of human
cytomegalovirus immediate early promoter. Since E2, a class I membrane glycoprotein, does not contain its own signal
peptide sequence at the 59 end, the bovine herpesvirus 1 (BHV-1) glycoprotein D signal sequence was fused in frame to the
E2 open reading frame (ORF) for proper processing of the E2 glycoprotein in both the recombinant viruses. Recombinant E2
protein expressed by BAV331 and BAV338 recombinant viruses was recognized by E2-specific monoclonal antibodies as a
53-kDa protein, which also formed dimer with an apparent molecular weight of 94 kDa. Insertion of an E2-expression cassette
in the E3 region did not effect the replication of recombinant BAV-3s. Intranasal immunization of cotton rats with these
recombinant viruses generated E2-specific IgA and IgG responses at the mucosal surfaces and in the serum. In summary,
these results show that the pestivirus glycoprotein can be expressed efficiently by BAV-3. In addition, mucosal immunization
with replication-competent recombinant bovine adenovirus 3 can induce a specific immune response against the expressed
antigen. © 2000 Academic Press
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Bovine viral diarrhea virus (BVDV) is a ubiquitous
pathogen of cattle, causing significant economic losses.
BVDV belongs to the genus pestivirus and contains a
single-stranded, positive-sense RNA molecule, 12.5 kb in
size (Renard et al., 1985). The RNA has a single open
reading frame (ORF) that encodes a number of structural
and nonstructural peptides that are cotranslationally and
posttranslationally cleaved from polyprotein precursors
(Collett et al., 1988a,b). Three putative BVDV structural
glycoproteins named Ems (gp44-48), E1 (gp25), and E2
gp53) were previously described (Thiel et al., 1991). E2 is
glycoprotein of 51 to 58 kDa in molecular weight (Donis
nd Dubovi, 1987), which induces strong neutralizing
ntibodies (Donis et al., 1988).
Seroepidemiological studies have shown that most
attle contract BVDV infection during their lifetime. Cur-
ently, inactivated and modified-live (MLV) vaccines are
sed to protect cattle from BVDV infection (Bolin, 1995).
owever, both types of vaccines have significant short-
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234omings. The major problem with MLV vaccines is that
hey are a potential source of in utero infection and/or
mmunosuppression (Liess et al., 1984; Roth and Kae-
erle, 1983). Since MLV vaccines need to replicate in the
ost, they are also susceptible to interference by mater-
al antibodies (Schultz, 1993). Thus, the use of immuno-
ominant BVDV proteins holds promise for the develop-
ent of efficacious vaccines for the control of BVDV.
lycoprotein E2 of BVDV has been successfully ex-
ressed in a number of expression systems, such as
aculovirus (Kweon et al., 1997), bovine herpesvirus 1
BHV-1) (Schmitt et al., 1999), and fowlpox vectors (Elahi
t al., 1999a); in addition, the E2 gene has been used in
NA immunization (Harpin et al., 1999).
We have characterized bovine adenovirus 3 (BAV-3)
Reddy et al., 1998, 1999a; Idamakanti et al., 1999; Baxi et
l., 1999) with the aim to develop it as an ideal vector for
nimal vaccination and gene therapy. BAV-3 was chosen
ecause of its low pathogenicity, species specificity, and
bility of the virus to grow to high titers in cell culture.
ecently, we constructed replication-defective (Reddy et
l., 1999b) and replication-competent recombinant BAV-3
Zakharatchouk et al., 1998; Baxi et al., 1999) expressing
HV-1 glycoprotein gD. Immunization of cattle with these
ecombinant BAV-3 expressing BHV-1 gD (BHV-1gD) in-
uced a protective immune response against challenge
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235INDUCTION OF IMMUNE RESPONSE BY BAV-3/BVDV RECOMBINANTSwith BHV-1 (Zakhartchouk et al., 1999). The use of recom-
inant BAV-3 for expression of vaccine antigen has an
nherent advantage over the other available systems,
ince BAV-3 in a natural pathogen of the cattle. In addi-
ion, it has been shown that, even in the presence of
AV-3-specific preexisting antibodies, the recombinant
AV-3 expressing BHV-1 gD was able to induce specific
mmune responses against both gD and BAV-3. These
esults strongly suggest that the presence of vector-
pecific antibodies should not hinder the use of recom-
inant BAV-3 vectors for immunization in calves (Zakhart-
houk et al., 1999).
Here, we describe the construction and characteriza-
ion of replication-competent (E3-deleted) recombinant
AV-3 expressing either natural or synthetic E2 glyco-
rotein of BVDV. In addition, we demonstrate that intra-
asal immunization of cotton rats with these recombi-
ant viruses induces BVDV E2-specific mucosal and sys-
emic immune responses.
RESULTS
n vitro translation and immunoprecipitation of BVDV
2 protein
In BVDV-infected cells, the E2 glycoprotein is pro-
uced as a result of proteolytic cleavage of the large
olyprotein encoding the glycoproteins Ems, E1, and E2
Collet et al., 1988a,b). Since the E2 glycoprotein lies at
he 39 end of the precursor polyprotein, it has its own
ransmembrane anchor at the 39 end, but lacks the signal
equence at its 59 end. To allow the proper intracellular
rocessing and transport of the E2 glycoprotein, the
ignal sequence of BHV-1 glycoprotein gD (Tikoo et al.,
990) was fused in frame to the 59 end of the E2ori (E2
riginal) or E2syn (E2 synthetic) open reading frames.
he identity of the modified E2 ORFs was verified by
ideoxynucleotide sequencing. To determine whether
he gD signal sequence was functional, two in vitro
xpression plasmids, pSP64-331 and pSP64-338, were
enerated in which the coding sequence of the E2ori or
2syn, respectively, was placed downstream of the SP6
romoter. In vitro translation of pSP64-331 and pSP64-
38 in vitro transcribed mRNA resulted in the synthesis
f a 44-kDa polypeptide (Fig. 1a, lane 1; Fig. 1b, lane 4),
hich was recognized by E2-specific antisera. In the
resence of canine microsomal membranes (Fig. 1a,
ane 2; Fig. 1b, lane 5), two polypeptides of 53 and 42 kDa
ere detected. Treatment of the E2 protein synthesized
n the presence of microsomal membranes with EndoH
esulted in the detection of only the 42-kDa protein (Fig.
a, lane 3; Fig. 1b, lane 6). Taken together, these results
uggested that the gD signal sequence of the modified
2 protein is cleaved after directing the E2 into the
icrosomal membranes for the addition of N-linked high-
annose oligosaccharides.
p
tonstruction of recombinant viruses
Initially, we assumed that expression of genes from
he cytoplasmic-replicating RNA viruses by recombinant
3-deleted BAV-3 would be similar to DNA virus genes
Zakhartchouk et al., 1998). Therefore, we constructed an
3-deleted full-length BAV-3 genomic clone (pFBAV339)
ontaining the BVDV E2ori coding sequence (devoid of
ny exogenous transcriptional element) inserted in the
3 region in the same transcriptional orientation as E3.
ransfection of fetal bovine retina cells with PacI-di-
ested pFBAV339 DNA resulted in the development of
ytopathic effects. The recombinant virus was named
AV339. Restriction enzyme analysis of the recombinant
irion DNA suggested that recombinant BAV339 con-
ained the E2ori gene (data not shown). However, immu-
oprecipitation analysis of BAV339-infected cells
howed little E2 glycoprotein at early time points and
one at later time points postinfection (p.i.) (Fig. 2b).
ince in vitro transcribed mRNA directed the synthesis of
2 glycoprotein (Fig. 2a), we assumed that failure to
etect E2 glycoprotein may be the result of aberrant
plicing or instability of E2 glycoprotein transcripts in the
uclei of BAV339-infected cells.
To express more of the E2 glycoprotein, we con-
tructed two full-length BAV-3 genomic clones containing
ither an E2syn gene (pFBAV331: E2syn gene nucleo-
ides modified relative to the natural E2 gene, to remove
he internal cryptic splice sites) or an E2ori gene under
he control of a human cytomegalovirus (HCMV) imme-
iate early (IE) promoter (pFBAV338) inserted in the E3
egion of pFBAV302 (Zakhartchouk et al., 1998). Both
FIG. 1. Immunoprecipitation of proteins synthesized by in vitro tran-
cription and translation of plasmids. (a) pSP64-331 and (b) pSP64-338.
roteins labeled with [35S]methionine in a cell-free rabbit reticulocyte
lysate in the absence (lanes 1 and 4) or presence of canine microsomal
membrane (lanes 2 and 5) were immunoprecipitated with E2-specific
BVDV antibody. [35S]-labeled proteins in the presence of canine micro-
omal membrane treated with EndoH enzyme at 37°C overnight (lanes
and 6). Molecular-size markers (M) are given in kDa.lasmids have the E2 glycoprotein in the same orienta-
ion as E3 (Fig. 3). Since the E2ori gene contains a
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236 BAXI ET AL.unique EcoRV restriction enzyme site and E2syn con-
tains two EcoRV sites (Fig. 3), we digested the plasmid
DNAs with EcoRV. As expected, compared to pFBAV302
(Fig. 4, lane a), EcoRV restriction enzyme digestion of
pFBAV331 (Fig. 4, lane b) and pFBAV338 (Fig. 4, lane c)
produced three and two bands, respectively. Transfec-
tions of fetal bovine retinal cells (FBRC) with PacI-di-
gested pFBAV331 or pFBAV338 plasmid DNAs produce
cytopathic effects within 15 days. Infected monolayers
were freeze-thawed and recombinant viruses named
BAV331 (pFBAV331) and BAV338 (pFBAV338) were
plaque-purified and propagated on Madin–Darby bovine
kidney cells (MDBK). The viral DNA was extracted and
analyzed by agarose gel electrophoresis after digestion
with EcoRV. As expected, the BAV331 (Fig. 4, lane e) and
BAV338 (Fig. 4, lane f) genomes contained four and three
bands, respectively, compared to the BAV302 (BAV302:
wild-type BAV3 with the E3 region deleted; Fig. 4, lane d)
genome, which contained only two bands. This sug-
gested that recombinants BAV331 and BAV338 contained
the E2 gene, which was confirmed by Southern blot
analysis (data not shown).
Growth of recombinant BAV-3
The growth kinetics of the three recombinant viruses
BAV302, BAV331, and BAV338 were analyzed in MDBK
cells. Cultures of MDBK cells were infected with the
viruses and cells harvested at 6, 12, 24, 36, 48, and 72 h
FIG. 2. Analysis of BAV339. (a) In vitro transcription/translation from
lasmid pSP64-339 in cell-free rabbit reticulocyte containing [35S]me-
hionine (lane 1) and immunoprecipitated with E2-specific BVDV poly-
lonal antibody (lane 2). (b) Immunoprecipitation analysis of BAV339-
nfected MDBK cells. Mock, BAV302-, and BAV339-infected MDBK cells
ere labeled with [3H]glucosamine, immunoprecipitated with E2-spe-
cific BVDV antibody, and analyzed on 10% reducing SDS gel. The arrow
indicates the E2-specific band. Molecular-size markers (MW) are given
in kDa.postinfection. Virus in each sample was released by
freeze-thawing and titered on MDBK cells. The resultsindicated a slight reduction in the yield of BAV331 virus at
24 and 36 h postinfection compared to that of BAV302
and BAV338 (Fig. 5). However, the final yields of all three
viruses at later times postinfection were nearly equiva-
lent and approached 108 TCID50/ml.
xpression of E2 by BAV331 and BAV338
To identify BVDV E2-specific polypeptide expressed by
he recombinant viruses, MDBK cells were infected with
ecombinant BAV302, BAV331, or BAV338 and metaboli-
ally labeled with [3H]glucosamine at 12, 18, 24, and 36 h
ostinfection. To monitor the expression of E2, infected
ell lysates were immunoprecipitated with E2-specific
onoclonal antibody (Paton et al., 1992). The immuno-
recipitated proteins were analyzed by SDS–polyacryl-
mide gel electrophoresis (PAGE). A 53-kDa protein (Fig.
a) was observed in cells infected with BAV331 and
AV338 under reducing conditions. Under nonreducing
onditions a 94-kDa band (Fig. 6b) was observed in
AV331- and BAV338-infected cells. No similar bands
ere visible in mock-infected (Fig. 6) or BAV302-infected
ells under reducing (Fig. 6a) or nonreducing (Fig. 6b)
onditions. This suggests that recombinants BAV331 and
AV338 expressed the E2 protein in vitro and the E2
rotein existed as a homodimer in the infected cells.
mmune response in cotton rats upon immunization
ith recombinant viruses
Cotton rats have been described as a useful small-
nimal model for studying the pathogenesis and immu-
ogenicity of BAV-3 (Mittal et al., 1996). To determine the
bility of BAV-3 recombinants to induce E2-specific im-
une responses, cotton rats were inoculated twice in-
ranasally, 3 weeks apart, with 107 plaque-forming units
(PFU) of BAV302, BAV331, or BAV338. Serum, lung
washes, and nasal washes were collected for analysis of
IgG and IgA antibodies, whereas lungs were collected
for analyzing the number of IgA antibody-secreting cells
(ASC). Immunization with BAV331 and BAV338 induced
higher IgA antibody response in lung and nasal washes
than did immunization with BAV302 (Figs. 7a and 7b).
Immune responses increased significantly (P , 0.05)
following booster immunization with BAV331 and
BAV338. E2-specific ASCs were found in the lungs of
BAV331- and BAV338-immunized cotton rats and the
number of ASC was significantly (P , 0.05) higher in the
BAV338-immunized group than in the BAV331- and
BAV302-immunized groups (Fig. 7c).
Cotton rat sera were assayed for BVDV E2-specific
antibodies in an indirect ELISA. Figure 7d shows that the
IgG response to BVDV E2 protein was significantly (P ,
0.05) higher in groups immunized with BAV331 and
BAV338 than in the group immunized with BAV302. The
BAV338-immunized group gave a significantly (P , 0.05)
higher IgG antibody response than did the BAV331-im-
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237INDUCTION OF IMMUNE RESPONSE BY BAV-3/BVDV RECOMBINANTSmunized group. The recombinants also induced BAV-3-
specific IgG antibody response (Fig. 7e), which was not
significantly different among the groups. Sera were also
tested for BVDV-neutralizing antibodies. Figure 7f shows
that immunization with BAV331 and BAV338 recombinant
viruses generated BVDV-neutralizing antibodies against
BVDV (Singer strain). The neutralizing ability of antibod-
ies generated after immunization with BAV338 was sig-
nificantly (P , 0.05) higher than that of the BAV331-
immunized group.
DISCUSSION
Recent advances in our ability to identify specific pro-
teins involved in the induction of protective immune re-
sponses, combined with developing novel and econom-
ical delivery systems, have laid the foundation for the
development of new, more efficacious viral vaccines.
FIG. 3. Schematic representation of the strategy used for plasmid a
omologous recombination in E. coli BJ5183 between SrfI-digested pF
Recombinant virus expressing E2 was obtained following transfection o
between pFBAV302 and XhoI–XbaI fragment containing the natural
pFBAV338. Recombinant virus expressing BVDV E2 was obtained fol
boxes), BAV3 genome (gray box), E2 open reading frame (open box), B
(thin line) are also indicated.Recently, recombinant human adenovirus has been used
as a delivery vehicle for BVDV vaccine antigens (Elahi et
a
ral., 1999b,c). Since use of human adenoviruses as a
vaccine delivery system in domestic animals is limited,
we have been attempting to develop species-specific
adenovirus as a delivery system for animal vaccination
(Zakhartchouk et al., 1998, 1999). In this report, we de-
scribe the construction and characterization of replica-
tion-competent BAV-3 expressing BVDV E2 glycoprotein
and testing their ability to induce mucosal and systemic
immune responses in cotton rats.
Foreign genes were previously inserted in E1 (Reddy
et al., 1999b), E3 (Zakhartchouk et al., 1998), or between
4 and the right ITR (Baxi et al., 1999) of the bovine
denovirus 3 genome. We chose the E3 region for BVDV
2 gene insertion based on the following observations:
i) the BAV-3 E3 region is nonessential and can be re-
laced with a foreign gene (Zakhartchouk et al., 1998), (ii)
3-deleted BAV-3 grows to high titers (Zakhartchouk et
mbinant virus construction. (a) Plasmid pFBAV331 was generated by
2 and XhoI–XbaI fragment containing the synthetic BVDV E2 (E2syn).
cells with PacI-digested pFBAV331. (b) The homologous recombination
2 (E2ori) under the control of HCMV promoter resulted in plasmid
transfection of PacI-digested pFBAV338 into FBRC cells. ITRs (black
gnal sequence (Sig), HCMV promoter (HCMV), and plasmid sequencend reco
BAV30
f FBRC
BVDV E
lowingl., 1998), and (iii) the antigens expressed from the E3
egion of BAV-3 induce protective immune responses in
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238 BAXI ET AL.animals (Zakhartchouk et al., 1999). However, our initial
ttempts to express BVDV E2ori gene proved unsuccess-
ul. The insertion of BVDV E2 ORF in the E3 region of
AV-3 resulted in the recovery of recombinant virus
BAV339), although the expression of the E2 protein was
ery low. One reason could be the presence of internal
ryptic splice sites in E2ori, which could result in the
ynthesis of inappropriate mRNAs in the nucleus. How-
ver, insertion of an intron upstream of E2ori did not alter
he expression of the protein (data not shown), although
similar approach was successful in obtaining desirable
xpression of bovine corona virus E3 glycoprotein in the
3 region of BAV-3 (Reddy et al., 2000). Alternatively, it is
possible that the transcripts are unstable in the nucleus
(Ku¨hnle et al., 1998). To enhance the expression of E2
protein, two different approaches were used. One of the
approaches to increase the expression of foreign gene
was to identify the splice-donor consensus sequences
(Mount, 1982) and alter the codons to remove these
sequences from the ORFs. To achieve this goal, the E2
ORF was resynthesized by changing the nucleotide se-
quence, which helped to remove the splice-donor con-
sensus sequences from the E2 sequence. The recombi-
nant virus thus generated from this synthetic E2 (BAV331)
expressed E2 protein in appreciable amounts, as shown
by immunoprecipitation with E2-specific monoclonal an-
tibodies. This suggests that the presence of internal
splice sites affects the proper processing of the E2-
specific transcripts. Previously, a similar approach was
FIG. 4. Restriction enzyme analysis of DNA samples of recombinant
plasmids and viruses. The DNA was digested with restriction enzyme
EcoRV, subjected to agarose gel electrophoresis, and stained with
ethidium bromide. Lane M, 1-kb ladder; lane a, pFBAV302; lane b,
pFBAV331; lane c, pFBAV338; lane d, BAV302; lane e, BAV331; and lane
f, BAV338.used successfully to express the BRSV G and BVDV E2
antigen in BHV-1 (Ku¨hnle et al., 1998; Schmitt et al., 1999).The second approach used to increase the expression of
E2 protein was to insert a heterologous promoter 59 to
the E2 gene. Insertion of HCMV IE promoter upstream of
the E2 ORF (BAV338) resulted in the expression of a
desirable amount of E2 protein. This suggests that dif-
ferent approaches have to be explored for the optimiza-
tion of expression of a foreign gene in the E3 region of
BAV-3.
Since BVDV E2 glycoprotein does not contain a signal
sequence at the 59 end, the BHV-1 gD signal was fused
in frame at the 59 end of the E2 ORF, for proper intracel-
lular transport and processing of E2 glycoprotein. Immu-
noprecipitation studies with E2-specific monoclonal an-
tibodies suggest that the E2 glycoprotein was processed
through the proper pathway upon insertion of the signal
sequence in both recombinant viruses, BAV331 and
BAV338. In addition, the recombinant E2 exhibited a
53-kDa molecular mass and appeared to form a 94-kDa
homodimer. Similar migration patterns of the monomeric
and homodimeric forms of the E2 glycoprotein were
observed in the BVDV-infected cells (Weiland et al.,
1990).
Cotton rats were developed as a useful small-animal
model for investigating the pathogenesis of BAV3 infec-
tion, as well as immune response to BAV3 recombinant
viruses (Mittal et al., 1996). Intranasal immunization of
cotton rats with BAV331 and BAV338 recombinant viruses
generated E2-specific mucosal and systemic immune
responses. In our study, immunization with BAV338 pro-
duced neutralization titers in cotton rats that varied from
1/128 to 1/1024, 16 days following booster immunization.
Although mice immunized with recombinant fowl pox
virus (Elahi et al., 1999a) or with a DNA vaccine (Harpin
et al., 1997, 1999), expressing E2 glycoprotein induced
FIG. 5. Kinetics of BAV302, BAV331, and BAV338 virus production.
Confluent monolayers of MDBK cells were infected at m.o.i. of 0.01 and
infected MDBK cells were harvested at the indicated times postinfec-
tion; the amounts of virus in cell lysate were determined by a TCID50
titration assay.
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239INDUCTION OF IMMUNE RESPONSE BY BAV-3/BVDV RECOMBINANTSE2-specific immune responses, the neutralization titers
were low with recombinant fowlpox virus (1/10 to 1/32) or
with DNA immunization (1/10 to 1/128). These results
suggest that BAV338 might be able to generate a protec-
tive immune response upon challenge in cattle.
Recombinant BAV338 induced a higher IgA response
on the mucosal surfaces of lung and nasal tract than did
recombinant BAV331. Similarly, higher E2-specific IgG
and BVDV-neutralizing titers were observed in the serum
of cotton rats immunized with BAV338 than with BAV331.
Because cotton rats support only limited replication of
BAV-3 (Mittal et al., 1996), consequently E2 expression
ay be limited in BAV331-infected cotton rats, since
AV331 uses the homologous BAV-3 E3/MLP promoter.
n contrast, since BAV338 contains E2 under the control
f a constitutive HCMV IE promoter, the E2 may be
xpressed for a longer duration in vivo, which could be
esponsible for induction of a strong immune response.
nother reason for induction of weak response by
AV331 may be that the synthetic E2-containing mRNA is
ess stable than that of the natural E2 gene. However, the
NA studies carried out using the synthetic genes for G
nd E2 glycoproteins of BRSV and BVDV, respectively
Ku¨hnle et al., 1998; Schmitt et al., 1999), show that the
ranscripts generated from these genes are fairly stable.
urther RNA and protein expression studies need to be
arried out to explore the various possibilities.
An effective vaccine to protect against the mucosal
respiratory and enteric) pathogens will be the one that
nduces protective immunity in the form of secretory IgA
ntibodies at the mucosal surfaces/site of entry of the
athogen. Since BVDV initiates infection at the mucosal
urfaces, primarily the respiratory tract (Bolin, 1990), the
FIG. 6. Immunoprecipitation analysis of BAV331- and BAV338-infected
r infected with BAV302, BAV331, or BAV338 and labeled with [3H]gl
radiolabeled cells were immunoprecipitated with E2-specific monoc
;53-kDa E2-specific band under reducing conditions in (A) and an ;9
markers (MW) are given in kDa.bserved induction of E2-specific IgA responses in the
ung and nasal passages of cotton rats and the presence
G
Gf ASC cells in the lungs after immunization suggests
hat the recombinant BAV-3 may be good vaccine candi-
ates for protection of animals from infection by BVDV.
In conclusion, we described the construction of re-
ombinant bovine adenovirus vectors expressing glyco-
rotein E2 of BVDV and showed that intranasal immuni-
ation of cotton rats with replication-competent BAV-3
xpressing E2 can induce antigen-specific mucosal and
ystemic immune responses. This work demonstrates
he potential of recombinant bovine adenovirus as a live
iral vector vaccine for the control of BVDV.
MATERIALS AND METHODS
ells and viruses
The WBR-1 strain of BAV-3 was cultivated in MDBK.
DBK and fetal bovine retina cells (FBRC) were grown in
agle’s minimum essential medium (MEM) supple-
ented with 10% fetal bovine serum. The viral DNA was
xtracted from virus-infected monolayers by the method
f Hirt (1967).
onstruction of recombinant plasmids
Construction of plasmid pFBAV338 and pFBAV339. A
glII-digested 1129-bp PCR fragment was isolated from the
ADL strain of BVDV by using oligonucleotides (1) Primer 1:
9-AGATCTATGACTTGGATTGCAAACCTG-39 and (2) Primer
: 59-AGATCTTGACTTCTGTTCTGATAAGACC-39 and was li-
ated to BglII-digested pSL301 plasmid, to create plasmid
SL301.E2. A 1097-bp NcoI–EcoRI fragment of plasmid
SL301.E2 was isolated and ligated to 83-bp complemen-
ary oligonucleotides [(a) 59-CATGGAAGGGCCGACATTG-
cells. Confluent monolayers of MDBK cells were either mock-infected
ine. At 12, 18, 24, and 36 h postinfection, proteins from lysates of
ntibody and analyzed on 10% SDS–PAGE. The arrows indicated an
E2-specific band under nonreducing conditions in (B). Molecular sizeMDBK
ucosam
lonal aCCGTGCTGGGCGCGCTGCTCGCCGTTGCGGTGAGCTT-
CCTACACACTTGGATTGCAAACCTG-39; (b) 59-AATTCAG-
w
a V E2-sp
t n Day 3
240 BAXI ET AL.GTTTGCAATCCAAGTGTGTAGGCAAGCTCACCGCAA-
CGGCGAGCAGCGCGCCCAGCACGGCCAATGTCGGCCC-
TTC-39 (encoding the N-terminal 20 amino acids of BHV-1
FIG. 7. Antibody response in cotton rats immunized with BAV331 (u
ashes on Days 21 and 37. (b) BVDV E2-specific IgA ELISA titers
ntibody-secreting cells 2 weeks after secondary immunization. (d) BVD
iters in serum on Day 37. (f) BVDV virus-neutralizing titers in serum oglycoprotein gD containing signal sequence and N-ter-
minal 6 amino acids of mature E2)], to create plasmidpSig.E2. A T4 polymerase-treated 1.18-kb NcoI–BglII frag-
ment of pSig.E2 was isolated and ligated to either T4-
treated HindIII–XhoI-digested polyCMV, to create plas-
38 (n ), and BAV302 (h). (a) BVDV E2-specific IgA ELISA titers in lung
sal washes on Days 21 and 37. (c) Frequency of E2-specific IgA
ecific IgG ELISA titers in serum on Day 37. (e) BAV-3-specific IgG ELISA
7.), BAV3
in namid pCMV.E2 or SrfI-digested pBAV301, to create plasmid
pBAV301.E2. A 1722-bp T4-treated BamHI–BglII fragment
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241INDUCTION OF IMMUNE RESPONSE BY BAV-3/BVDV RECOMBINANTSof pCMV.E2 was ligated to SrfI-digested pBAV301, to
create plasmid pBAV301.cE2. The recombinant BAV-3 ge-
nome containing E2 (pFBAV339) or E2 under the control
of an HCMV promoter (pFBAV338) was generated by
homologous DNA recombination in E. coli BJ5183 be-
tween SrfI-linearized pFBAV302 (Zakhartchouk et al.,
1998) and a 3473-bp XhoI–XbaI fragment of pBAV301.E2
or SrfI-linearized pFBAV302 and a 4015-bp XhoI–XbaI
fragment of pBAV3.cE2.
Construction of plasmid pFBAV331. A 3605-bp NcoI–
MluI fragment of plasmid pBSK-BVDV (containing a syn-
thetic E2 gene; Bayer AG, Germany) was isolated and
ligated to 68-bp oligonucleotides (59-CATGGAAGGG-
CCGACATTGGCCGTGCTGGGCGCGCTGCTCGCCGTT-
GCGGTGAGCTTGCCTACGCGT-39) (Tikoo et al., 1990), to
create plasmid p329a. Plasmid p329a was linearized by
MluI and ligated to MluI-digested 474-bp PCR fragment
(Primer 3: 59-CGACGCGTCTCGATTGCAAACCTGACTT-
39; Primer 4: 59-GGGGAAACGCGTTTATATGTCCG-39), to
create plasmid p329b. Finally, a T4-treated 1225-bp
NcoI–BamHI fragment was ligated to SrfI-digested
pBAV301 to create plasmid pBAV301.E2syn. The recom-
binant BAV-3 genome containing a synthetic E2 gene
(pFBAV331) was generated by homologous recombina-
tion in E. coli BJ5183 between SrfI-linearized pFBAV302
and a 3518-bp XbaI–XhoI fragment of pBAV301.E2syn.
Transfection of cells
FBRC were grown in 60-mm dishes in MEM medium
with 10% FBS. Cells were transfected with 10 mg of
acI-digested pFBAV331 or pFBAV338 recombinant plas-
id DNA using the Ca12-phosphate method (Hermiston
t al., 1998). Following transfection, cells were main-
ained in MEM containing 2% FBS at 37°C for 15–20 days
ntil cytopathic effects appeared. Cells showing 50%
ytopathic effects were harvested and freeze-thawed
hree times, and recombinant virus was plaque-purified
n MDBK cells (Zakhartchouk et al., 1998).
n vitro transcription/translation
Plasmid DNA (1 mg) (pSP64-331, pSP64-338, or
SP64-339) was in vitro transcribed with SP6 polymer-
se as described by the supplier (Promega, Madison,
I). RNA was translated in vitro for 2 h at 30°C using
rabbit reticulocyte lysate containing 20 mCi [35S]me-
hionine. After synthesis, the in vitro translated pro-
eins were analyzed on SDS–PAGE with or without
mmunoprecipitation. To carry out enzymatic treat-
ent, immunoprecipitated proteins were eluted from
rotein A–Sepharose in 0.5% SDS and digested with
ndoH as described previously (Tikoo et al., 1993). The
igested proteins were finally analyzed on SDS–PAGE
el.mmunoprecipitations
Monolayers of MDBK cells were infected with 10 PFU
f recombinant or wild-type virus. After 90 min of absorp-
ion, cells were washed and incubated in MEM contain-
ng 2% FBS. At different times p.i., the cells were incu-
ated in glucose-free Dulbecco’s modified Eagle’s me-
ium (DMEM) for 1 h before labeling with
3H]glucosamine (100 mCi/ml). After 12 h of labeling, cells
were washed with PBS and stored at 270°C. All the
samples were analyzed at the same time by harvesting
the cells in radioimmunoprecipitation buffer (RIPA buffer:
150 mM NaCl, 10 mM Tris [pH 7.8], 1% Triton X-100, 1%
sodium deoxycholate, 0.1% SDS). Immunoprecipitations
were carried out with monoclonal antibodies against E2
(Paton et al., 1992) and complexes were captured with
protein A–Sepharose beads. Precipitates were washed
in RIPA buffer and proteins were separated on a 10%
SDS–PAGE. Labeled proteins were visualized by autora-
diography.
Animal experiment
Four- to 6-week-old cotton rats of either sex were
divided into three groups of nine animals each. After
anesthetizing the cotton rats with halothane, animals
were immunized twice at Day 1 and Day 21 by the
intranasal route with 50–100 ml of inoculum containing
107 PFU of individual recombinant virus. Blood samples
were also collected at Days 1, 21, and 37 after primary
immunization to examine for the development of BVDV-
E2-specific antibody response by enzyme-linked immu-
nosorbent assays (ELISA) and by virus neutralization
(VN) assays. Four animals in each group were killed at
Days 21 and 37 after primary inoculation by an overdose
of halothane. The lungs and nasal secretions were col-
lected separately for analysis of BVDV-E2-specific muco-
sal IgA responses by ELISA. The lungs were also collected
at Days 21 and 37, to determine the frequency of BVDV-E2-
specific IgA antibody-secreting cells by ELISPOT.
Preparation of lymphocytes from the lungs
The lungs were removed aseptically, chopped, and
incubated in complete medium containing MEM supple-
mented with 10% FBS, 2 mM L-arginine, 1 mM sodium
pyruvate, 100 mM nonessential amino acids, 10 mM
EPES buffer, 100 U/ml penicillin G, 100 mg/ml strepto-
mycin solution, 150 U/ml collagenase A, and 50 U/ml
DNase I for 1 h. The homogenized suspension was then
gently passed through a plastic mesh with a 5-ml syringe
plunger and washed with MEM. Finally, the lymphocyte
population was separated by centrifugation of the lung
suspension on a discontinuous Percoll gradient. The
cells were washed with MEM, resuspended in complete
medium, and incubated for 1 h in a tissue-culture flask to
attach adherent cells. The nonadherent cell population
was then resuspended and used in the ELISPOT assay.
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Antigen-specific ELISPOT assays were carried out as
described previously (Papp et al., 1997). Briefly, nitrocel-
lulose-based, 96-well microtiter plates were coated with
purified BVDV E2 (1 mg/well) in coating buffer (50 mM
aHCO3/Na2CO3, pH 9.6) at 4°C overnight. The plates
were washed with sterile PBS and further incubated for
1 h at room temperature in complete medium. Lympho-
cytes were added at a concentration of 1 3 106 cells in
00 ml/well and incubated overnight at 37°C. Following
ncubation, cells were first washed with sterile water,
hen with PBS containing 0.05% Tween-20 (PBST). Bio-
inylated anti-rat IgG (Zymed Laboratories, San Fran-
isco, CA) or rabbit anti-rat IgA followed by biotinylated
oat anti-rabbit secondary antibodies were used for the
etection of antigen-specific IgG or IgA. All plates were
urther incubated with streptavidin-alkaline phosphatase,
ollowed by spot development with 5-bromo-4-chloro-3-
ndolyl phosphate (BCIP)-nitro blue tetrazolium (NBT)
ubstrate.
ntigen-specific ELISA
The levels of antibodies specific for BVDV E2 in sera,
ung, and nasal washes was determined by ELISA. Im-
unolon-2 microtiter plates were coated with purified E2
0.6 mg/well) in coating buffer at 4°C overnight. The
plates were washed with PBST between each step.
All samples were serially diluted in PBST–BSA and
incubated overnight at 4°C. Antigen-specific IgG was
detected by horseradish peroxidase-conjugated goat
anti-rat IgG (Cedarlane Laboratories, Hornby, Ontario,
Canada). Antigen-specific IgA was measured by rabbit
anti-rat IgA, followed by incubation with horseradish per-
oxidase-conjugated goat anti-rabbit IgG. Reactions were
visualized with streptavidin-alkaline phosphate conju-
gate and BCIP/NBT.
Serum neutralization assay
Twofold serial dilutions of heat-inactivated sera were
incubated with BVDV for 2 h at room temperature in a
total volume of 50 ml medium. A total of 100 ml media was
added to the serum/virus mixture and incubated with
MDBK cells in 48-well tissue-culture plates. After 1-h
adsorption, the mixture was removed and the cells were
washed twice with PBS and overlaid with 0.7% low-
melting agarose. Plaques were counted and titers were
expressed as reciprocals of the highest antibody dilution
that caused 50% reduction in the number of plaques
relative to the control wells that were infected with un-
treated virus.
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